EUVIMEDEUVIMED entdecken
Open Access

EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function

Yusuke Isshiki, Xi Chen, Matt Teater, Ioannis Karagiannidis, Henna Nam, Winson Cai, Cem Meydan, Min Xia, Hao Shen, Johana Gutierrez, Vigneshwari Easwar Kumar, Sebastián E Carrasco und 13 weitere

Cancer Cell · 2025-01 · 43 (1) · 49-68.e9

DOI: 10.1016/j.ccell.2024.11.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2025-01. Verfasst von Yusuke Isshiki und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Immunotherapy, Adoptive, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 88-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCI NIH HHS, FDA HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T cell-based immunotherapies have demonstrated effectiveness in treating diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) but predicting response and understanding resistance remains a challenge. To address this, we developed syngeneic models reflecting the genetics, epigenetics, and immunology of human FL and DLBCL. We show that EZH2 inhibitors reprogram these models to re-express T cell engagement genes and render them highly immunogenic. EZH2 inhibitors do not harm tumor-controlling T cells or CAR-T cells. Instead, they reduce regulatory T cells, promote memory chimeric antigen receptor (CAR) CD8 phenotypes, and reduce exhaustion, resulting in a decreased tumor burden. Intravital 2-photon imaging shows increased CAR-T recruitment and interaction within the tumor microenvironment, improving lymphoma cell killing. Therefore, EZH2 inhibition enhances CAR-T cell efficacy through direct effects on CAR-T cells, in addition to rendering lymphoma B cells immunogenic. This approach is currently being evaluated in two clinical trials, NCT05934838 and NCT05994235, to improve immunotherapy outcomes in B cell lymphoma patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enhancer of Zeste Homolog 2 ProteinImmunotherapy, AdoptiveLymphoma, FollicularLymphoma, Large B-Cell, DiffuseT-LymphocytesAnimalsHumansMiceCell Line, TumorImmunotherapyReceptors, Chimeric AntigenTumor MicroenvironmentClinical Trials as Topic

Stichwörter der Autor:innen

CAR-TDLBCLEZH2T cell immunotherapybispecific antibodiesfollicular lymphoma

Substanzen

Enhancer of Zeste Homolog 2 ProteinEZH2 protein, humanReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA.
  • Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA; Institute for Computational Biomedicine, Weill Cornell Medicine, Cornell University, New York, NY,…
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Institute for Computational Biomedicine, Weill Cornell Medicine, Cornell University, New York, NY, USA; Department of Physiology and Biophysics, Weill Cornell Medicine, Cornell University, New York, NY, USA.
  • Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York City, NY, USA; Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, and Rockefeller Unive…
  • Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York City, NY, USA.

Förderung

  • NHLBI NIH HHS
  • NCI NIH HHS
  • FDA HHS
  • Japan Society for the Promotion of Science
  • Leukemia and Lymphoma Society
  • ASH Foundation
  • Lymphoma Research Foundation of America
  • Kite Pharma Inc

Zitieren

APA

Isshiki, Y., Chen, X., Teater, M., Karagiannidis, I., Nam, H., Cai, W., Meydan, C., Xia, M., Shen, H., Gutierrez, J., Easwar Kumar, V., Carrasco, S. E., Ouseph, M. M., Yamshon, S., Martin, P., Griess, O., Shema, E., Porazzi, P., Ruella, M., …, & Béguelin, W. (2025). EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function. Cancer Cell, 43(1), 49-68.e9. https://doi.org/10.1016/j.ccell.2024.11.006

Vancouver

Isshiki Y, Chen X, Teater M, Karagiannidis I, Nam H, Cai W, et al. EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function. Cancer Cell. 2025;43(1):49-68.e9. doi:10.1016/j.ccell.2024.11.006

BibTeX
@article{Isshiki2025,
  author = {Isshiki, Yusuke and Chen, Xi and Teater, Matt and Karagiannidis, Ioannis and Nam, Henna and Cai, Winson and Meydan, Cem and Xia, Min and Shen, Hao and Gutierrez, Johana and Easwar Kumar, Vigneshwari and Carrasco, Sebastián E and Ouseph, Madhu M and Yamshon, Samuel and Martin, Peter and Griess, Ofir and Shema, Efrat and Porazzi, Patrizia and Ruella, Marco and Brentjens, Renier J and Inghirami, Giorgio and Zappasodi, Roberta and Chadburn, Amy and Melnick, Ari M and Béguelin, Wendy},
  title = {EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function},
  journal = {Cancer Cell},
  year = {2025},
  volume = {43},
  number = {1},
  pages = {49--68.e9},
  doi = {10.1016/j.ccell.2024.11.006}
}
Kostenlos starten →